Stuelpnagel John R's Form 4 filing
10x Genomics, Inc. (TXG) · filed Nov 3, 2021
- Accession no.
- 0001567619-21-019298
- Filed
- Nov 3, 2021
- Trade date
- Nov 1, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions. Open-market sales total $817.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stuelpnagel John RCIK 0001189140 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2021 | Class A Common Stock | SSaleDisposed | −100 | $160.33 | −$16,033 | 361,516 | Direct | |
| Nov 1, 2021 | Class A Common Stock | SSaleDisposed | −100 | $160.75 | −$16,075 | 361,416 | Direct | |
| Nov 1, 2021 | Class A Common Stock | SSaleDisposed | −100 | $161.52 | −$16,152 | 361,316 | Direct | |
| Nov 1, 2021 | Class A Common Stock | SSaleDisposed | −1,494 | $163.10F2 | −$243,671.4 | 359,822 | Direct | |
| Nov 1, 2021 | Class A Common Stock | SSaleDisposed | −2,906 | $163.89F3 | −$476,264.34 | 356,916 | Direct | |
| Nov 1, 2021 | Class A Common Stock | SSaleDisposed | −300 | $164.58F4 | −$49,374 | 356,616 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $162.50 to $163.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $163.50 to $164.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $164.55 to $164.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.